Overview

Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

Status:
Unknown status

Trial end date:
2018-01-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Treating a patient's T cells in the laboratory may help the T cells kill more tumor cells when they are put back in the body. Giving laboratory-treated T cells after chemotherapy may be an effective treatment for breast cancer. PURPOSE: This phase II trial is studying how well giving laboratory-treated T cells after second-line chemotherapy works in treating women with HER2/neu-negative metastatic breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Barbara Ann Karmanos Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cyclophosphamide